<DOC>
	<DOCNO>NCT02325037</DOCNO>
	<brief_summary>The purpose First-in-Human study evaluate safety tolerability single ascend oral dos GLPG1837 give healthy subject , compare placebo . Also , safety tolerability multiple ascend oral dos GLPG1837 give healthy subject daily 14 day compare placebo , evaluate . Furthermore , course study single multiple oral dose administration , amount GLPG1837 metabolite present blood urine ( pharmacokinetics ) characterize . The effect food pharmacokinetics GLPG1837 metabolite also evaluate . The potential cytochrome P450 ( CYP ) 3A4 induction repeat dose GLPG1837 explore well .</brief_summary>
	<brief_title>First-in-Human Single Multiple Dose GLPG1837</brief_title>
	<detailed_description />
	<criteria>Males female nonchild bear potential 1850 year age ( include ) Subjects must body mass index 1830 kg/mÂ² ( include ) Subjects must judge good health base upon result medical history , physical examination , vital sign , 12lead electrocardiogram laboratory finding A subject know hypersensitivity study drug ingredient significant allergic reaction drug Concurrent participation participation within 8 week prior initial study drug administration drug/device biologic investigational research study participation within 15 week prior initial study drug administration investigational research study antibody administration A subject active drug alcohol abuse within 2 year prior initial study drug administration Current sexually active ( and/or child wish ) male ; contraception method use Pregnant lactate woman woman childbearing potential</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>